On January 17, 2019 Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, reported that its President and CEO, Peter L. Hoang, will present a corporate overview at the upcoming Phacilitate Leaders World & World Stem Cell Summit 2019 on Wednesday, January 23, 2019 (Press release, Marker Therapeutics, JAN 17, 2019, View Source;utm_medium=email&utm_campaign=investor_alerts&utm_content=Marker+Therapeutics+to+Present+at+the+Phacilitate+Leaders+World+%26+World+Stem+Cell+Summit+2019 [SID1234532705]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details
Title: Efficacy without Toxicity: A Multi-Antigen, Non Gene-Modified Therapy That May Address Current CAR-T Limitations
Date: Wednesday, January 23, 2019
Time: 2:20 p.m. EST
Location: Hyatt Regency, Miami, FL